ProCure Proton Therapy Center

Currently enrolling patients in the following clinical trials

Pediatric Brain Tumor Consortium

- A Feasibility study of SAHA combined with Isotretinoin and chemotherapy in infants with embryonal tumors of the central nervous system ~In affiliation with Lurie's Children Hospital Chicago, IL
    - clinicaltrials.gov identifier NCT00867178

Children's Oncology Group

- A phase II multi-institutional trial of focal radiotherapy with concomitant carboplatin as a radiosensitizer and the prospective analysis of survivin, an inhibitor of apoptosis, as a biomarker in children with newly diagnosed non-metastatic ependymoma and minimal residual disease post-operatively ~In affiliation with Lurie's Children Hospital Chicago, IL
    - clinicaltrials.gov identifier NCT01088035

Proton Collaborative Group

- Evaluation tracking project: a prospective chart review of patients treated with proton therapy
    - clinicaltrials.gov identifier NCT01255748
- GU002-10 Low Risk Prostate
    - 5 fractions (38 Gy) vs. 44 fractions (79.2 Gy). Randomized trial.
    - A phase III prospective randomized trial of standard-fractionation vs. hypo fractionation with proton radiation therapy for low risk adenocarcinoma of the prostate
    - INCLUSIONS: path within a year, H&P within 90 days of start, PSA <10 within 90 days, T1-T2a within 90 days, IPSS ≤ 16, Gleason 2-6
    - EXCLUSIONS: Previous prostate surgery or radiation for cancer, prior chemo for prostate cancer, active rectal diverticulitis Crohn's affecting the rectum or UC.
    - clinicaltrials.gov identifier NCT 01230866
- GU003-10 Intermediate Risk Prostate
    - 28 fractions (70 Gy) +/- ADT (4-6 months, MD discretion). Randomized trial.
    - Phase III study of mildly hypo-fractionated image guided proton beam radiation therapy with or without androgen suppression for intermediate risk adenocarcinoma of the prostate.
    - INCLUSIONS: path within a year, H&P within 90 days of start, at least 1 of the following: Gleason 7, PSA 10-20, or T2b-T2c, IPSS within 90 days of start.
    - EXCLUSIONS: pelvic lymph nodes> 1.5 cm in greatest dimension, previous prostate surgery or radiation for cancer, chemo or prior androgen deprivation.
    - clinicaltrials.gov indentifier NCT01492972
- GU004-11 High Risk Prostate
    - 44 fractions (79.2 Gy) with ADT +/- chemo. Randomized Trial
    - INCLUSIONS: path within a year, H&P within 90 days of start, prostate cancer with at least 1 high grade feature (PSA, Gleason or T stage), no evidence of distant mets or lymph node involvement
    - EXCLUSIONS: previous prostate cancer surgery or pelvic radiation, ADT prior to radiation is not allowed.
    - Phase II/III study of dose-escalated external beam radiation with or without chemotherapy for high risk adenocarcinoma of the prostate.
    - clinicaltrials.gov indentifier NCT01603420

UPenn Recurrent Tumors Trial

- UPCC #23309
    - Retreating any non-CNS malignancy except high volume thoracic as that is closed. H&N, low volume thoracic, pelvis, abdomen, extremities
    - INCLUSIONS: recurrence must be in or near prior treated field. KPS > 60 Age > 18
    - EXCLUSIONS: prior RT < 3months from planned start, pregnant, KPS < 60